Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154745 | 0.84 | AURKA (0.56) | AURKAAURKBCHEK1FLT3TTK | |
| SCHEMBL8240285 | 0.84 | AURKA (0.56) | AURKAAURKBCHEK1FLT3TTK | |
| SCHEMBL8247571 | 0.71 | AURKA (0.58) | AURKAAURKBCHEK1TTKCCNA2 | |
| SCHEMBL8239744 | 0.71 | AURKA (0.64) | AURKAAURKBCHEK1FLT3TTK | |
| SCHEMBL8240135 | 0.71 | AURKA (0.58) | AURKAAURKBFLT3TTK | |
| SCHEMBL8241005 | 0.71 | AURKA (0.64) | AURKAAURKBCHEK1FLT3TTK | |
| SCHEMBL8241222 | 0.71 | AURKA (0.58) | AURKAAURKBCHEK1CCNA2CDK2 | |
| SCHEMBL8241235 | 0.71 | AURKA (0.81) | AURKAAURKBCHEK1CCNA2CDK2 | |
| SCHEMBL8246210 | 0.71 | AURKA (0.55) | AURKAAURKBFLT3TTK | |
| SCHEMBL8240570 | 0.71 | AURKA (0.63) | AURKAAURKBCHEK1FLT3TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | AURKA 40/4885AURKB 27/4885CHEK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.